| Prev Close | 11.52 |
| Open | 11.55 |
| Day Low/High | 11.28 / 11.74 |
| 52 Wk Low/High | 2.38 / 6.56 |
| Volume | 5.24M |
| Avg Volume | 3.98M |
| Exchange | NASDAQ |
| Shares Outstanding | 171.77M |
| Market Cap | 1.94B |
| EPS | -0.70 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
The San Diego firm is scheduled to present positive preliminary data for two clinical studies of sitravatinib in non-small cell lung cancer at a symposium in Chicago on Friday.
I really like how these three charts are shaping up on Array.
Array to Advance Preclinical Program for Autoimmune Disorders
Levi & Korsinsky announces it has commenced an investigation of Array BioPharma Inc.
Akari Therapeutics, Array BioPharma and Amicus Therapeutics were among the biotech movers in premarket trading on Wednesday.
Arrary reacquired MEK inhibitor in 2015 as part of FTC settlement with Novartis.
Here's what traders are saying.
Crude oil prices continue their decline on Tuesday, pulling the energy sector lower and the S&P 500 from its records achieved last week.
Array BioPharma, Advaxis, Merrimack Pharmaceuticals and Insys Therapeutics were among the biotech stock movers in premarket trading on Tuesday.
Stock futures point to a lower open on Tuesday as traders return to Wall Street after the long Memorial Day weekend.
Array BioPharma (Nasdaq:ARRY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the companies have entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of...
- Novel combinations of binimetinib, Opdivo® (nivolumab) and Yervoy® (ipilimumab) to be studied in colorectal cancer patients
Myriad Genetics, Spectrum Pharmaceuticals and Array BioPharma were among the biotech stock movers in early trading on Wednesday.
Novartis exec argues the FTC should keep its hands off when pharmaceutical products are in early stages of development.
Here's how to potentially rake in some fat profits off a number of hot breakout setups.
Here's how to trade six of the most active names on the market this afternoon.
CytomX Therapeutics, Aevi Genomic Medicine and Esperion Therapeutics were among the biotech stock movers in premarket trading on Monday.
- NRAS-mutant melanoma NDA withdrawn based on thorough discussions with FDA and following late cycle review meeting -
Jim Cramer is bullish on PaylPal, CH Robinson Worldwide, Texas Instruments and NXP Semiconductors.
Jim Cramer highlight's Buffett's confidence in American businesses and stocks, and his critique of high fees charged by money managers.
Here are Friday's top research calls, including an upgrade for Ford and downgrades for Eaton, Altria and Ralph Lauren.
Here are Monday's top research calls, including downgrades for Air Products and Colgate-Palmolive, and upgrades for Disney and Noble.
Jim Cramer thinks Take-Two Interactive and Activision Blizzard have winning potential.
The idea of buying American and hiring American is good news for defense, ag and energy stocks, says Jim Cramer.
The Loxo phase II 'basket' study of larotrectinib is expected to complete patient enrollment in early 2017 and report results in the second half of the year.
